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Key messages 
What is already known about this subject?
 ► Clinical practice guidelines (CPGs) can guide clini-
cians on how to treat patients and offer a possible 
support to optimise the diagnostic/therapeutic pro-
cess in a difficult field.
 ► CPGs are designed to support the decision-making 
processes in patient care and their content is based 
on systematic reviews of clinical evidence, the main 
source for evidence-based care.
What does this study add?
 ► This work is dedicated to the identification of exist-
ing CPGs in the field of rare and complex diseases 
and to the identification of physicians and patients 
unmet needs.
 ► This is the preparatory work to define a strategy of 
implementation of existing CPGs and/or develop-
ment of new CPGs.
How might this impact on clinical practice?
 ► The implementation and development of new CPGs 
will support the harmonization of care in rare and 
complex connective tissue diseases in line with 
the mission of the European Reference Network 
ReCONNET.
INTRODUCTION
An impressive number of almost 5000–8000 
rare diseases affect the daily lives of around 
30 million people in the European Union 
(EU) and many of those affected by a rare or 
complex condition do not have access to diag-
nosis and high-quality treatment.
European Reference Networks (ERNs) 
are virtual networks involving healthcare 
providers (HCPs) across Europe with the aim 
to tackle complex or rare diseases and condi-
tions that require highly specialised treat-
ment and a concentration of knowledge and 
resources. ERNs offer the potential to give 
patients and doctors across the EU access to 
the best expertise and timely exchange of life-
saving knowledge, making knowledge travel 
more than patients.1
Following the first call for proposals in 
July 2016, the first ERNs were approved in 
December 2016 and launched in March 
2017 in Vilnius during the 3rd conference 
on ERNs, where their kick off meetings 
took place. At their inception, the networks 
comprised more than 900 highly specialised 
healthcare units located in 313 hospitals in 26 
EU countries.2 From this date, the 24 ERNs 
are working on a range of thematic issues, 
including rare connective tissue diseases, 
bone disorders, childhood cancer, metabolic 
disorders and immunodeficiency.
To achieve ERN status, network members 
applied to a Call from the European Commis-
sion. This application was assessed by an Inde-
pendent Assessment Body which completed 
reports on each applicant. The Board of 
Member States then decided whether or not 
to approve an ERN application, and it was 
based on the main key criteria, represent 
by: patient-centred and clinically led, the 
engagement of at least 10 members in at least 
eight countries, a strong independent assess-
ment, the fulfilment of Network and member 
criteria, the endorsement and approval by 
national authorities. Over the next 5 years, 
ERNs are expected to reinforce their capacities 
to benefit thousands of EU patients suffering 
from a rare or complex condition; moreover, 
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many of the ERN initiative receives support from several 
EU funding programmes, including Horizon 2020, the 
Health Programme and the Connecting Europe Facility.
The ERN ReCONNET (European Reference Network 
on Rare and Complex Connective Tissue and Musculo-
skeletal Diseases)3 is the ERN aimed at improving the 
management of Rare Connective Tissue and Musculo-
skeletal Diseases across the EU. The ERN ReCONNET, 
involves 26 HCPs, from eight different EU countries: 
Belgium, France, Germany, Italy, Netherlands, Portugal, 
Romania and Slovenia. Of note, the contribution is on 
a voluntary basis. The Network covers the following 10 
rare and complex connective tissue diseases, which were 
identified based on the epidemiology of the diseases 
(any disease affecting fewer than 5 people in 10 000 is a 
rare disease) and suggestion of the steering committee 
members (for complex diseases: systemic lupus erythe-
matosus and Sjögren’s syndrome): systemic sclerosis, 
mixed connective tissue diseases, idiopathic inflamma-
tory myopathies, antiphospholipid syndrome, undiffer-
entiated connective tissue diseases, IgG4-related diseases, 
relapsing polychondritis, systemic lupus erythematosus, 
Sjögren’s syndrome, Ehlers Danlos syndromes.3
One of the most relevant added value of the ERN 
ReCONNET is the involvement of Patients’ Representa-
tives within all the activities of the Network. In fact, an 
intense collaboration has been established with the ERN 
ReCONNET European Patient Advocacy Group (ePAGs). 
Their role is to provide patients’ opinion and input in 
the activities of the 10 work packages (WPs), to give 
the opinion and views of the patient groups, to collabo-
rate in the evaluation of how the ERN acts on feedback 
from patients, to review the performance of the ERN 
& contributing to research, to promote and encourage 
a patient-centric approach, to develop and disseminate 
patients’ information, to ensure that patient rights and 
choices are taken into account in decision-making and to 
identify relevant national patients’ organisations to work 
with the ERN’s HCPs.
CLINICAL PRACTICE GUIDELINES
Clinical practice guidelines serve as a great equaliser in 
the field of rare diseases: as a matter of fact, they can 
mean the difference between no care/substandard care 
and patients living longer, healthier lives with fewer 
complications. Guidelines, whether designed to support 
correct and early diagnosis or care, can serve as a blue-
print of excellence, to advise clinicians (general practi-
tioners and specialists) on how to treat patients in a way 
that reflects the best possible updated knowledge and 
therefore generating the best possible outcomes. Clinical 
practice guidelines are not fixed protocols that must be 
followed but are intended for healthcare professionals 
and providers to be considered as a possible support to 
optimise their diagnostic/therapeutic process in a diffi-
cult field.
Additionally, since the Network wishes to be as inclu-
sive as possible, other HCPs, after approval of the 
Steering Committee, but not officially involved in the 
ERN ReCONNET joined the work on Clinical Practice 
Guidelines.
The ePAGs Representatives have intensely collabo-
rated to the project, organising and participating to 
regular web conferences, providing their input into the 
WPs and participating to different meetings. Moreover, 
the input of the ePAGs Representatives was particularly 
important in WP3, where they actively contributed to the 
preparation of the final manuscripts realising a specific 
paragraph on patients’ unmet needs on Clinical Practice 
Guidelines.
The whole work of WP3 was based on the eminent 
definition of the Institute of Medicine according which 
Clinical Practice Guidelines are ‘statements that include 
recommendations, intended to optimise patient care, 
that are informed by a systematic review of evidence and 
an assessment of the benefits and harms of alternative 
care options’.4
Before planning the development of any potential new 
Clinical Practice Guidelines, the first-year activities of the 
network aimed at assessing the state of the art’ on Clin-
ical Practice Guidelines available for rare and complex 
Connective Tissue Diseases. The work has been made 
by conducting systematic literature reviews (SLRs) and 
through the recognition of official documents from 
scientific societies about Clinical Practice Guidelines for 
the different subgroups of rare and complex Connective 
Tissue Diseases.
Specifically, the overall activities had been subdivided 
in five steps:
Step 1—Identification of existing guidelines. A SLR based 
on controlled terms (MeSH and Emtree) and keywords 
of the diseases and publication type (guidelines) was 
performed on Medline (Pubmed) and Embase databases 
without specific temporal limits. Moreover, in order to 
implement the list of guidelines provided, each disease 
group performed a hand search of further relevant 
documents.
Step 2—Discussion on the existing guidelines. In order to 
create a starting point to discuss among each disease 
group, the experts evaluated Clinical Practice Guidelines 
following the AGREE II tool checklist (an international 
tool to assess the quality and reporting of Clinical Prac-
tice Guidelines) which was used only as guidance, not for 
formal appraisal. At this stage, a formal methodological 
evaluation with the AGREE II tool was not performed, 
since such an activity is already planned for the 2-year 
activities on WP3 also in the perspective of an eventual 
adaptation of the, existing guidelines. Each disease group 
organised more than one web meeting in order to check 
the work status and to follow the discussion performed in 
each group, including different members of different EU 
countries, perfectly fulfilling the rationale of the planned 
activities for WP3 and the real spirit of the ERNs.
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Step 3—Preliminary report on guidelines assessment. During 
the ERN ReCONNET meeting on 5 November 2017 in 
San Diego (ACR 2017), each disease group Represen-
tative presented a preliminary report on the assessment 
performed and preliminary considerations on potential 
gaps on existing Clinical Practice Guidelines.
Step 4—State of the art on CPGs. A state of the art on Clinical 
Practice Guidelines has been performed for each disease 
covered by the ERN ReCONNET and is presented in the 
articles included in the present supplement together 
with the results of the Step 5—Identification of unmet needs.
The literature review has highlighted the existence of 
partially sufficient Clinical Practice Guidelines for some 
rare and complex Connective Tissue Diseases (Systemic 
Lupus Erythematosus, Idiopathic Inflammatory Myop-
athies, Systemic Sclerosis, Sjögren Syndrome), while 
demonstrating the absence of evidence-based Clinical 
Practice Guidelines for other rare and complex Connec-
tive Tissue Diseases (Antiphospholipid syndrome, 
Relapsing Polychondritis, Mixed Connective Tissue 
Disease, Ehlers-Danlos Syndromes, Undifferentiated 
connective tissue disease, IgG4 Related Diseases). This 
might be explained by the absence of sufficient evidence 
data to support the development of these recommenda-
tions and highlights the need of future studies, which 
could be supported by the ERN ReCONNET in collab-
oration with specific study groups and scientific soci-
eties (already established for some Clinical Practice 
Guidelines).
In addition, the supplement also includes a contribu-
tion written by the Health Economic Group of Scuola 
Superiore Sant’Anna (Pisa) who is actively involved in 
the network for its considerable expertise in pharma-
coeconomics. The paper is aimed at obtaining a state of 
the art of rare diseases policies and initiatives in the ERN 
ReCONNET countries, collecting and analysing the rare 
diseases national plans of all the eight countries of the 
ERN ReCONNET participants.
Finally, this supplement offers all together, the ‘state 
of the art’ on Clinical Practice Guidelines available for 
complex and rare Connective Tissue Diseases and might 
serve also as knowledge background for the develop-
ment of the tools for the analysis of organisational and 
economic aspects related to the diagnosis and manage-
ment of rare and complex connective tissue diseases.
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